Needham & Company Maintains a 'Hold' on Vertex (VRTX); Q1 Preview

April 17, 2012 7:40 AM EDT
Get Alerts VRTX Hot Sheet
Price: $505.75 -2.07%

Rating Summary:
    38 Buy, 7 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company maintains a 'Hold' on Vertex (NASDAQ: VRTX).

Analyst, Alan Carr, said, "Vertex is scheduled to announce 1Q12 financial results on April 26. Our U.S. 1Q12 Incivek net sales estimate is $372M (was $375M), based on IMS data, and our Kalydeco net sales estimate is $7.0M. Kalydeco was launched in early February 2012. Our 1Q12 GAAP EPS estimate is $0.41 (was $0.42). We are cautious overall given expected competitive pressures in HCV and challenges in developing a companion drug for Kalydeco to address the F508del CF population."

(FY13 lowered from $3.23 to $3.08)

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $35.49 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Needham & Company, Earnings